WASHINGTON, LONDON and HONG KONG, Sept. 6, 2011 /PRNewswire/ —
SuperNova Diagnostics®, Inc., a privately-held global
diagnostics company for human and non-human health applications,
today announced that Neil J. Campbell, President and CEO, will be
presenting at the Rodman & Renshaw Global Investment Conference
on September 13, 2011 from 10:50 -11:15 am EDT in the Metropolitan
West room of the Waldorf-Astoria in New York, NY.
The presentation will include an overview of SuperNova’s
proprietary point-of-care (POC) and point-of-use (POU) diagnostic
technology targeting four industry sectors: human health, animal
health, industrial and biodefence/biosecurity. A live webcast
and 90 day archive of the presentation will be available at http://www.wsw.com/webcast/rrshq20/spdi.
“Point-of-care and point-of-use diagnostics represent a
multi-billion dollar market with an annual growth rate of 20
percent, making it one of the most significant investing and
technological opportunities over the next five to 10 years,” said
Mr. Campbell. “SuperNova is at the forefront of this revolution,
having developed our AmpCrystal® platform to provide an array
of diagnostic capabilities, from patient treatment to pathogen
detection. We welcome the opportunity to showcase our vision and
technology to the many investors and industry leaders at the Rodman
& Renshaw Global Investment Conference.”
About SuperNova Diagnostics®, Inc.
SuperNova® is a development-stage diagnostics company with a
proprietary platform for conducting diagnostics at the site of
interest with point-of-care in human health and point-of-use for
non-human health applications. A powerful proprietary
nanochemistry, AmpCrystal®, can deliver novel, next
generation performance for pathogens, proteins, and directly
measure DNA without PCR with ultra-low sensitivity and specificity
while no
‘/>”/>
